-
-
REFERENCES
[1] Békés M., Langley D.R. and Crews C.M. (2022). PROTAC targeted protein degraders: The past is prologue. Nat. Rev. Drug Discov. 21:181−200. DOI:10.1038/s41573-021-00371-6 [2] Sathe G. and Sapkota G.P. (2023). Proteomic approaches advancing targeted protein degradation. Trends Pharmacol. Sci. 44:786−801. DOI:10.1016/j.tips.2023.08.007 [3] Akimov V., Barrio-Hernandez I., Hansen S.V.F. et al. (2018). UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat. Struct. Mol. Biol. 25:631−640. DOI:10.1038/s41594-018-0084-y [4] Donovan K.A., An J., Nowak R.P. et al. (2018). Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane radial ray syndrome. eLife 7:e38430. DOI:10.7554/eLife.38430 [5] Gadd M.S., Testa A., Lucas X. et al. (2017). Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13:514−521. DOI:10.1038/nchembio.2329 -
ABOUT THIS ARTICLE
Cite this article:
Zhou V. (2026). Degradomics turns TPD into systems pharmacology. The Innovation Drug Discovery 1:100039. https://doi.org/10.59717/j.xinn-drugdisc.2026.100039
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Zhou V. (2026). Degradomics turns TPD into systems pharmacology. The Innovation Drug Discovery 1:100039. https://doi.org/10.59717/j.xinn-drugdisc.2026.100039
Format
Content
DownLoad:
-
Figure 1.
Degradomics as a systems pharmacology layer for targeted protein degradation
